Search Results
Dec 02, 2025, 08:56 ET Executives from Pacific Gas & Electric, LG NOVA, Vivint, Samsung Electronics, Constellation Energy, Alarm.com, and more to speak at Parks Associates' 20th annual CONNECTIONS™ Summit at CES® 2026
President, Open Home FoundationScott Tjaden, Manager, IT Digital Transformation & Partnership Strategy, Constellation EnergyDave Wechsler, Chief Business Officer, PlumeMatthew Wootton, Co-Founder & CTO, IvaniGeorge Yianni, CTO & Founder,
More news about: Parks Associates
Dec 02, 2025, 08:00 ET 7shifts Celebrates the Leaders Shaping Hospitality with The Restaurant Innovators 2025 Awards
Chris Gurrie, Haley Armitage, Nick Lalli, Jason Leeds, Antonette Palacios, Jessie Love, Jake Lonie, Dakotah Pompura, Brandon O'Donnell, Megan Yaffey and Dave GarciaThe Culture Catalyst: Honors an individual that helped foster high employee satisfaction and retention through outstanding
More news about: 7shifts
Dec 02, 2025, 07:23 ET Carolinas AGC Announces 2026 Board of Directors
Edward Griffith, Trident Construction Immediate Past Chair: Ty Edmondson, T. A. Loving Company President & CEO: Dave Simpson, CAE, Carolinas AGC Highway-Heavy Chair: Aaron Bogner, Conti Civil Building Division Chair: David Wise, Harper
More news about: Carolinas AGC
Dec 01, 2025, 11:21 ET Generate:Biomedicines lance des essais mondiaux de phase 3 sur le GB-0895, un anticorps anti-TSLP à longue durée d'action pour le traitement de l'asthme sévère, conçu grâce à l'IA
fardeau des maladies respiratoires chroniques. »Résultats de la phase 1 présentés au Congrès international 2025 de l'ERS Le Dr Dave Singh, professeur de pharmacologie clinique et de médecine respiratoire à l'université de Manchester et directeur médical de la Medicines Evaluation
More news about: Generate:Biomedicines
Dec 01, 2025, 11:15 ET Dechert Elevates 17 Attorneys to Partnership
accelerate our strategy across our global platform and deliver market‑leading results for clients," said Dave Forti, co-chair of Dechert.The new partners include:Dave Darr, Finance and Real Estate, CharlotteMatthew Duxbury, Financial Services, LondonLindsay
More news about: Dechert LLP
Dec 01, 2025, 10:46 ET Generate:Biomedicines rozpoczyna globalne badania III fazy nad GB-0895, przeciwciałem o długim działaniu skierowanym przeciwko limfopoetynie zrębu grasicy (TSLP) przeznaczonym do leczenia astmy ciężkiej, opracowanym przy użyciu sztucznej inteligencji
obciążenie związane z przewlekłymi chorobami układu oddechowego".Wyniki fazy 1 przedstawione podczas konferencji ERS 2025 Dr Dave Singh, profesor farmakologii klinicznej i medycyny układu oddechowego na Uniwersytecie w Manchesterze oraz dyrektor medyczny w Medicines Evaluation
More news about: Generate:Biomedicines
Dec 01, 2025, 10:00 ET Grass League Announces Sale of Las Vegas Action Franchise for $1 Million, Marking a Major Milestone in League Expansion
leaders across sports, entertainment, and business. Other notable owners and ownership groups in the league include Good Good Golf, LA Dodgers Manager Dave Roberts, former PGA Tour Player and Travis Mathew co-founder John Mallinger, and current PGA Tour star Wyndham Clark among other notable names who are
More news about: MMPR MARKETING
Dec 01, 2025, 08:51 ET Top 5%: Moore, Schulman & Moore Continues Excellence with 2025 Super Lawyers Distinction
1, 2025 /PRNewswire/ -- Moore, Schulman & Moore, APC is proud to announce that five of its attorneys—Founding Partners Erik Moore and Dave Schulman, and Partners Julie Westerman, Kevin Polis, and Jeremy Boyer—have been selected for inclusion in the 2025 Super Lawyers list. This
More news about: Moore, Schulman & Moore, APC
Dec 01, 2025, 08:00 ET Dave & Buster's Surpasses $20 Million in Donations to Make-A-Wish®
Dave & Buster's launched its fundraising efforts with an initial goal of $120,000 in its first year, ultimately raising nearly $500,000 in 2012 alone. That early success laid the foundation for a long-term commitment to community support. Since then, Dave & Buster's has consistently
More news about: MAKE-A-WISH AMERICA
Dec 01, 2025, 08:00 ET Sub Club Is Back and Better Than Ever at Subway®, Get Every Fourth Footlong Free
was to reduce the number of visits needed to earn something of real value. With that focus, we're introducing our richest loyalty program ever," said Dave Skena, Chief Marketing Officer, North America. "That's why we're also giving Sub Club members a chance to earn some extra bread this holiday season."Join
More news about: Subway Restaurants
Dec 01, 2025, 08:00 ET Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
ability to design efficient, signal-rich clinical studies and rapidly translate our ADC portfolio into potentially impactful therapies for patients," said Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics.Dr. Dugan joins Whitehawk following more than three decades of oncology drug development
More news about: Whitehawk Therapeutics, Inc.
Dec 01, 2025, 06:00 ET Generate:Biomedicines 將啟動 GB-0895 全球三期臨床試驗，此為運用人工智能科技研發的長效抗 TSLP 抗體，專治嚴重哮喘
的第三期臨床試驗，既體現我們對嚴重哮喘病人的承諾，也彰顯我們研發平台的實力——致力開發能減輕慢性呼吸道疾病負擔的藥物。」在 ERS 2025 上發表的第一期試驗結果 University of Manchester 臨床藥理學與呼吸系統醫學教授、藥物評估單位醫療總監 Dave Singh 醫學博士，於阿姆斯特丹舉行的 2025 年歐洲呼吸學會 (European Respiratory Society; ERS) 國際大會上發表了 GB-0895 的第 I 期臨床試驗數據。在這項針對 96 名輕度至中度氣喘患者的研究中，GB-0895 在廣泛劑量範圍（10 毫克至 1,200
More news about: Generate:Biomedicines
Dec 01, 2025, 06:00 ET Generate:Biomedicines начинает 3 фазу глобальных клинических испытаний разработанного с использованием ИИ препарата GB-0895 -- антитела длительного действия, направленного на блокировку TSLP при тяжелых случаях астмы
сократить число хронических респираторных заболеваний».Результаты 1 фазы исследований, представленные на ERS 2025 Дэйв Сингх (Dave Singh), доктор медицинских наук, профессор клинической фармакологии и респираторной медицины в University of Manchester и медицинский директор подразделения
More news about: Generate:Biomedicines
Dec 01, 2025, 06:00 ET Generate:Biomedicines spúšťa globálne štúdie 3. fázy liečiva GB-0895 - anti-TSLP protilátky s dlhým pôsobením na liečbu ťažkej astmy, vyvinutej pomocou AI
platformy priniesť lieky, ktoré by mohli znížiť záťaž chronických respiračných ochorení."Výsledky 1. fázy prezentované na ERS 2025 Dave Singh, MD, profesor klinickej farmakológie a respiračnej medicíny na University of Manchester a medicínsky riaditeľ Útvaru pre hodnotenie liekov, prezentoval
More news about: Generate:Biomedicines
Dec 01, 2025, 06:00 ET Generate:Biomedicines zahájí globální studie fáze 3 přípravku GB-0895, dlouhodobě působícího protilátky proti TSLP pro těžké astma vyvinuté pomocí umělé inteligence
přinášet léky, které by mohly snížit zátěž chronických respiračních onemocnění."Výsledky fáze 1 představené na kongresu ERS 2025Dave Singh, MD, profesor klinické farmakologie a respirační medicíny na Univerzitě v Manchesteru a lékařský ředitel Medicines Evaluation Unit, představil
More news about: Generate:Biomedicines
Dec 01, 2025, 06:00 ET Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
to bring forward medicines that could reduce the burden of chronic respiratory disease."Phase 1 Results Presented at ERS 2025Dave Singh, MD, professor of clinical pharmacology and respiratory medicine at the University of Manchester and medical director at the Medicines Evaluation
More news about: Generate:Biomedicines
Dec 01, 2025, 06:00 ET Generate:Biomedicines Memulai Penelitian Fase 3 Global Tentang GB-0895, Antibodi Anti-TSLP Kerja Lambat yang Direkayasa AI Untuk Asma Berat
untuk menyediakan obat-obatan yang dapat meringankan beban penyakit pernapasan kronis."Hasil Fase 1 Dipresentasikan di ERS 2025 Dave Singh, MD adalah profesor Clinical Pharmacology and Respiratory Medicine di University of Manchester dan Medical Director di Medicines Evaluation Unit.
More news about: Generate:Biomedicines
Dec 01, 2025, 06:00 ET Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
to bring forward medicines that could reduce the burden of chronic respiratory disease."Phase 1 Results Presented at ERS 2025Dave Singh, MD, professor of clinical pharmacology and respiratory medicine at the University of Manchester and medical director at the Medicines Evaluation
More news about: Generate:Biomedicines
Dec 01, 2025, 06:00 ET Generate:Biomedicines startet globale Phase-3-Studien mit GB-0895, einem langwirksamen Anti-TSLP-Antikörper für schweres Asthma, der mit KI entwickelt wurde
Belastung durch chronische Atemwegserkrankungen verringern könnten."Phase-1-Ergebnisse auf dem ERS-Kongress 2025 vorgestellt Dave Singh, MD, Professor für klinische Pharmakologie und Atemwegsmedizin an der Universität Manchester und medizinischer Direktor der Medicines Evaluation
More news about: Generate:Biomedicines
Dec 01, 2025, 06:00 ET Generate:Biomedicines deve iniciar estudos globais de Fase 3 do GB-0895, um anticorpo anti-TSLP de ação prolongada para asma grave desenvolvido com IA
medicamentos que poderiam reduzir o impacto das doenças respiratórias crônicas."Resultados da Fase 1 Apresentados na ERS 2025 Dave Singh, MD, professor de farmacologia clínica e medicina respiratória da Universidade de Manchester e diretor médico da Unidade de Avaliação de Medicamentos,
More news about: Generate:Biomedicines
Dec 01, 2025, 06:00 ET Generate:Biomedicines iniciará ensayos clínicos de fase 3 a nivel mundial del GB-0895, un anticuerpo anti-TSLP de acción prolongada para el asma grave diseñado con IA
podrían reducir la incidencia de las enfermedades respiratorias crónicas".Resultados de la fase 1 presentados en ERS 2025: el Dr. Dave Singh, profesor de Farmacología Clínica y Medicina Respiratoria en la Universidad de Manchester y director médico de la Unidad de Evaluación de Medicamentos,
More news about: Generate:Biomedicines
Dec 01, 2025, 06:00 ET Generate:Biomedicines inicia estudios globales de fase 3 de GB-0895
medicamentos que podrían reducir la carga de enfermedades respiratorias crónicas".Resultados de la fase 1 presentados en ERS 2025 El Dr. Dave Singh, profesor de farmacología clínica y medicina respiratoria de la Universidad de Manchester y director médico de la Unidad de Evaluación de Medicamentos,
More news about: Generate:Biomedicines
Nov 26, 2025, 18:26 ET "WE CAN FORGIVE EACH OTHER": TROUTMAN FOR AMERICA SAYS THANKSGIVING IS A TIME FOR "BEAUTIFUL" AMERICA TO FORGIVE AND FIND UNITY AGAIN
however."We have to be very forgiving but also very smart. Dave Min was arrested for a very serious DUI recently and he lied about how much he drank," Troutman says. "I'm trying to be very forgiving of him, but when you risk people's lives like Dave Min did—and then lie about it—that really shows a lack
More news about: Troutman For America
Nov 26, 2025, 08:00 ET Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference in New York City, NY
More news about: Whitehawk Therapeutics, Inc.
Nov 25, 2025, 14:42 ET Starlight's Give Happiness Campaign Rallies Celebrities and Community Fundraisers to help 80,000 kids during the Holidays
year, musician and long-time supporter Dave Koz raised $200,000 to help deliver $10,000 custom pallets of toys along his 20-city holiday tour route, bringing play to children across the country. The effort kicked off at Children's Hospital Los Angeles, where Dave distributed the toys and performed
More news about: Starlight Children’s Foundation